This finding reveals that ACAD11 may play a key role in the progression of ccRCC through a dual mechanism - regulating tumor metabolic reprogramming and affecting tumor-immune microenvironment interactions, making it a highly potent target for therapeutic intervention. This evidence concerns the gene ACAD11 and neoplasm.